4'-deoxy-4'-iododoxorubicin profile

4'-deoxy-4'-iododoxorubicin: lipophilic derivative of doxorubicin which differs from the parent compound in substitution of hydroxyl group on the daunosamine sugar moiety [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	108161
CHEBI ID	47897
SCHEMBL ID	62735
MeSH ID	M0150374

Synonym
i-dox
iodo-dox
fce-21954
5,12-naphthacenedione, 10-(((2r,4s,5s,6s)-4-aminotetrahydro-5-iodo-6-methyl-2h-pyran-2-yl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8s,10s)-
fce 21954
5,12-naphthacenedione, 7,8,9,10-tetrahydro-10-((4-aminotetrahydro-5-iodo-6-methyl-2h-pyran-2-yl)oxy)-8-(hydroxyacetyl)-1-methoxy-6,8,11-trihydroxy-, (2r-(2-alpha(8s,10s),4-beta,5-beta,6-beta))-
nsc-378901
idx ,
4'-deoxy-4'-iododoxorubicin
CHEBI:47897
4'-iodo-4'-deoxydoxorubicin
iododoxorubicin
83997-75-5
(8s,10s)-10-{[(2r,4s,5s,6s)-4-amino-5-iodo-6-methyltetrahydro-2h-pyran-2-yl]oxy}-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
unii-65jh75i9jx
65jh75i9jx ,
SCHEMBL62735
4-iodo-4-deoxydoxorubicin
Q27120844
wp 154;4'-iodo-4'-deoxydoxorubicin; fce 21954
10-[(4-amino-5-iodo-6-methyloxan-2-yl)oxy]-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
DTXSID301004258

Excerpt	Reference	Relevance
"7 X 10(-7) M for 50% cell survival) which were not toxic if administered in the dark."	( Photocytotoxicity of anthracyclines upon laser excitation in their long-wavelength absorption bands. Andreoni, A; Colasanti, A; Malatesta, V; Roberti, G, 1991)	0.28
" Treatments induced a significant widening of the S alpha T segment, but I-DXRol was significantly less toxic than I-DXR or DXR."	( Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Bernardini, N; Bevilacqua, G; Danesi, R; Del Tacca, M; La Rocca, RV; Marchetti, A, 1990)	0.28
"In a prospective phase I trial involving 35 patients with metastatic carcinoma, we tested a pharmacokinetic strategy for guiding dose escalation of the anthracycline 4'-iodo-4'-deoxydoxorubicin (I-DOX), a new analogue reported to be more potent and less toxic than doxorubicin."	( Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. Ballinari, D; Bonadonna, G; Casali, P; Collins, JM; Gianni, L; Surbone, A; Tarella, C; Viganò, L, 1990)	0.28

Excerpt	Reference	Relevance
" We describe correlations between pharmacokinetic parameters and toxicity."	( Pharmacodynamic and pharmacokinetic aspects of iodo-doxorubicin. Becker, K; Hossfeld, DK; Mayer, U; Mross, K; Zeller, W, 1992)	0.28
"4); the metabolite was cleared from the plasma with an elimination half-life of 15."	( Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. Armand, JP; Huet, S; Hurteloup, P; Klink-Alakl, M; Recondo, G; Robert, J, 1992)	0.28
" The pharmacokinetic parameters also implied metabolic differences between species."	( Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. Basileo, G; Edwards, DM; Efthymiopoulos, C; Fraier, D; Marrari, P; Pianezzola, E; Strolin-Benedetti, M, )	0.13
"In a prospective phase I trial involving 35 patients with metastatic carcinoma, we tested a pharmacokinetic strategy for guiding dose escalation of the anthracycline 4'-iodo-4'-deoxydoxorubicin (I-DOX), a new analogue reported to be more potent and less toxic than doxorubicin."	( Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials. Ballinari, D; Bonadonna, G; Casali, P; Collins, JM; Gianni, L; Surbone, A; Tarella, C; Viganò, L, 1990)	0.28
" 4'-Deoxy-4'-I-DX disappears from plasma with a terminal half-life of 5 h, which is half the terminal half-life of doxorubicin (11 h), and its efficiency of absorption after oral administration is 27%."	( Pharmacokinetics of 4'-deoxy-4'-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. Carsana, R; Formelli, F; Pollini, C, 1987)	0.27
"We have studied the practical implications and acceptability to patients of pharmacokinetic studies in 34 women receiving anthracyclines for advanced breast cancer."	( Patient acceptability and practical implications of pharmacokinetic studies in patients with advanced cancer. Dobbs, NA; Gregory, WM; Ramirez, AJ; Richards, MA; Towlson, KE; Twelves, CJ, 1993)	0.29

Excerpt	Relevance	Reference
" A multicenter study attempted to develop a dosing schedule to confirm those results."	( A multicenter phase II trial of 4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Barlogie, B; Cheson, BD; Dispenzieri, A; Gertz, MA; Geyer, SM; Kyle, RA; Lacy, MQ; Merlini, G; Palladini, G, 2002)	0.31

Class	Description
organoiodine compound	An organoiodine compound is a compound containing at least one carbon-iodine bond.
primary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
tertiary alpha-hydroxy ketone	An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	10 (16.95)	18.7374
1990's	41 (69.49)	18.2507
2000's	8 (13.56)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (19.40%)	5.53%
Reviews	6 (8.96%)	6.00%
Case Studies	2 (2.99%)	4.05%
Observational	0 (0.00%)	0.25%
Other	46 (68.66%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
iodine Iodine: A nonmetallic element of the halogen group that is represented by the atomic symbol I, atomic number 53, and atomic weight of 126.90. It is a nutritionally essential element, especially important in thyroid hormone synthesis. In solution, it has anti-infective properties and is used topically.. diiodine : Molecule comprising two covalently bonded iodine atoms with overall zero charge..	2	1	0	diatomic iodine	nutrient
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.78	2	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	1.97	1	0	mitomycin	alkylating agent; antineoplastic agent
thymidine [no description available]	2.38	2	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.1	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
uridine [no description available]	2.38	2	0	uridines	drug metabolite; fundamental metabolite; human metabolite
leucine Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.	3.33	2	0	amino acid zwitterion; L-alpha-amino acid; leucine; proteinogenic amino acid; pyruvate family amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
acridines Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.	3.1	1	0	acridines; mancude organic heterotricyclic parent; polycyclic heteroarene	genotoxin
thiazoles [no description available]	2	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
congo red Congo Red: An acid dye used in testing for hydrochloric acid in gastric contents. It is also used histologically to test for AMYLOIDOSIS.. Congo Red : An indicator dye that is blue-violet at pH 3.0 and red at pH 5.0.	3.1	1	0	bis(azo) compound
thioflavin t thioflavin T: RN given refers to chloride; structure. thioflavine T : An organic chloride salt having 2-[4-(dimethylamino)phenyl]-3,6-dimethyl-1,3-benzothiazol-3-ium as the counterion. It is widely used to visualise and quantify the presence of amyloids, both in vitro and in vivo.	2	1	0	organic chloride salt	fluorochrome; geroprotector; histological dye
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.48	8	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	1.98	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	3.1	1	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.1	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	1.97	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	2.67	3	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
methoxy-morpholinyl-doxorubicin methoxy-morpholinyl-doxorubicin: structure in first source	1.98	1	0	anthracycline antibiotic; morpholines; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
5-iminodaunorubicin 5-iminodaunorubicin: RN given refers to parent cpd	1.97	1	0
adriamycinol doxorubicinol : A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.	1.97	1	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
proline Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.	3.33	2	0	amino acid zwitterion; glutamine family amino acid; L-alpha-amino acid; proline; proteinogenic amino acid	algal metabolite; compatible osmolytes; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	3.1	1	0
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	1.98	1	0
daunorubicinol daunorubicinol: main metabolite of daunomycin. (13S)-13-dihydrodaunorubicin : The (13S)-diastereomer of 13-dihydrodaunorubicin.	1.97	1	0	13-dihydrodaunorubicin
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	3.1	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
azidopine azidopine: structure given in first source	1.98	1	0	benzamides
ruboxyl ruboxyl: paramagnetic nitroxyl analog of rubomycin	1.97	1	0
4'-iodo-4'-deoxydoxorubicinol 4'-iodo-4'-deoxydoxorubicinol: structure given in first source	4.28	4	1
esorubicin esorubicin: RN given refers to parent cpd; synthesized deriv of doxorubicin	1.97	1	0
adriamycin aglycone adriamycin aglycone: RN given refers to (8S-cis)-isomer	1.97	1	0
idarubicinol idarubicinol: RN given refers to (7S-(7alpha,9alpha,9(R*))-isomer	1.97	1	0	anthracycline
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	1.98	1	0
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.93	1	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.93	1	0
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	3.1	1	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies	Trials
Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.	8.97	11	4
Cardiac Diseases [description not available]	1.98	1	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	3.77	2	1
Colorectal Cancer [description not available]	4.06	3	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	3.77	2	1
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	4.06	3	1
Cancer of Colon [description not available]	2.38	2	0
ATLL [description not available]	1.98	1	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.38	2	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	1.98	1	0
Carcinoma, Ductal, Breast An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.	3.37	1	1
Breast Cancer [description not available]	4.06	3	1
Metastase [description not available]	9.06	3	1
Local Neoplasm Recurrence [description not available]	3.37	1	1
Breast Neoplasms Tumors or cancer of the human BREAST.	4.06	3	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	4.06	3	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	3.37	1	1
Carcinoma, Lobular A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.	3.37	1	1
Cancer of Lung [description not available]	4.61	6	1
Lung Neoplasms Tumors or cancer of the LUNG.	4.61	6	1
Carcinoma, Non-Small Cell Lung [description not available]	3.37	1	1
Cardiac Failure [description not available]	3.37	1	1
Leukocytopenia [description not available]	3.37	1	1
Thrombopenia [description not available]	3.37	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.37	1	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	3.37	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.37	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.37	1	1
Gammapathy, Monoclonal [description not available]	2.91	1	0
Paraproteinemias A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.	2.91	1	0
Benign Neoplasms [description not available]	3.81	4	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.81	4	0
CJD (Creutzfeldt-Jakob Disease) [description not available]	1.99	1	0
Rida [description not available]	1.99	1	0
Creutzfeldt-Jakob Syndrome A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))	1.99	1	0
Carcinoma, Anaplastic [description not available]	2.39	2	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	2.39	2	0
Disease Exacerbation [description not available]	3.38	1	1
Cardiac Arrest, Sudden [description not available]	3.38	1	1
Death, Sudden, Cardiac Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)	3.38	1	1
Anasarca [description not available]	2	1	0
Lassitude [description not available]	2	1	0
Granuloma, Hodgkin [description not available]	2	1	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	2	1	0
Fatigue The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.	2	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2	1	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	3.32	2	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	3.32	2	0
Amyloid Deposits [description not available]	2	1	0
Acute Confusional Senile Dementia [description not available]	3.32	2	0
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	3.32	2	0
Polyneuropathy, Acquired [description not available]	2	1	0
Polyneuropathies Diseases of multiple peripheral nerves simultaneously. Polyneuropathies usually are characterized by symmetrical, bilateral distal motor and sensory impairment with a graded increase in severity distally. The pathological processes affecting peripheral nerves include degeneration of the axon, myelin or both. The various forms of polyneuropathy are categorized by the type of nerve affected (e.g., sensory, motor, or autonomic), by the distribution of nerve injury (e.g., distal vs. proximal), by nerve component primarily affected (e.g., demyelinating vs. axonal), by etiology, or by pattern of inheritance.	2	1	0
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	1.98	1	0
Experimental Neoplasms [description not available]	2.38	2	0
Carcinoma, Epidermoid [description not available]	4.33	2	2
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	4.33	2	2
Cancer of Liver [description not available]	2.38	2	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.38	2	0
Arrhythmia [description not available]	2.38	2	0
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.38	2	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.97	1	0
Blood Diseases [description not available]	1.97	1	0
Hematologic Diseases Disorders of the blood and blood forming tissues.	1.97	1	0
Carcinoma, Oat Cell [description not available]	1.97	1	0
Glial Cell Tumors [description not available]	2.66	3	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.66	3	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	1.97	1	0
Delayed Hypersensitivity [description not available]	1.97	1	0
Granulocytic Leukemia, Chronic [description not available]	1.97	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	1.97	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.97	1	0
B16 Melanoma [description not available]	6.97	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.97	1	0
Experimental Leukemia [description not available]	2.37	2	0
Cardiomyopathies, Primary [description not available]	1.97	1	0
Experimental Mammary Neoplasms [description not available]	1.97	1	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1.97	1	0

4'-deoxy-4'-iododoxorubicin

Description

Cross-References

Synonyms (22)

Research Excerpts

Toxicity

Pharmacokinetics

Dosage Studied

Drug Classes (3)

Research

Studies (59)

Market Indicators

Research Demand Index: 10.38

Study Types